适应自然存在的蛋白质 - - 费里丁,调节OX40的内在激动性
Whitney Shatz-Binder1,2, Caleigh M Azumaya3, Brandon Leonard4
1Protein Chemistry, Genentech Inc., South San Francisco, California 94080, United States.
Bioconjugate chemistry
|April 9, 2024
概括
费里丁作为癌症治疗的多功能药物输送系统 (DDS). 研究人员在ferritin上显示了anti-OX40抗体碎片,激活了T细胞途径以杀死瘤细胞.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 材料科学 材料科学 材料科学
背景情况:
- 费里丁是一种自我组装的蛋白质,是基于聚合物的药物递送系统 (DDS) 的潜在替代品.
- 向瘤亡因子受体超级家族 (TNFRSF) 成员是一个有前途的抗癌策略.
- 受体激活需要联体寡合化和细胞表面定.
研究的目的:
- 为了评估费里丁作为T细胞激动症的药物递送系统 (DDS).
- 为了证明费里丁用于显示癌症治疗的抗体碎片的实用性.
主要方法:
- 调整费里丁子以显示抗OX40抗体碎片的多价值显示.
- 评估费里显示抗体阵列激活细胞表面受体的能力.
主要成果:
- 费里丁子被成功修改为显示抗OX40抗体碎片.
- 这些阵列通过细胞表面聚类诱导了通路激活,证明了T细胞激动性.
- 费里丁作为DDS的多功能性得到了证实.
结论:
- 费里丁是一种可开发和多功能平台,用于药物输送.
- 基于费里的药物输送系统通过使T细胞激进作用显示出癌症治疗的潜力.
更多相关视频
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
958
08:32Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
12.8K
相关概念视频
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
Opioid Receptors: Overview
764
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
764
Spare Receptors
3.5K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
3.5K
Regulation of Metabolism
9.4K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.4K
Allosteric Regulation
57.9K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.9K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
